“As an investigator of THR-149, I was encouraged to see the results from its clinical phase 1 trial", Pravin Dugel, M.D., says.
In 2019, Oxurion announced positive topline data for the compound THR-149, a highly potent plasma kallikrein inhibitor to treat diabetic macular edema (DME).
Jean Feyen, PhD., Chief Scientific Officer, and Andy De Deene, M.D., Global Head of Development, explain why Oxurion decided to focus on non-VEGF pathways.